Drug Patent List
First Filer Exclusivity TimelineNew
Newsletter
Weekly Digest

Pharsight

Neurocrine Drug Patent Portfolio

Neurocrine owns 3 orange book drugs protected by 27 US patents Given below is the list of Neurocrine's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12582634 Synthetic Methods For Preparation Of 4-(2-Chloro-4-Methoxy-5-Methylphenyl)-N-[(1S)-2-Cyclopropyl-1-(3-Fluoro-4-Methylphenyl)Ethyl]-5-Methyl-N-Prop-2-Ynyl-1,3-Thiazol-2-Amine 12 Jan, 2043
Active
US12128033 Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine 09 Jun, 2041
Active
US10940141 Methods for the administration of certain VMAT2 inhibitors 10 Aug, 2040
Active
US11026931 Methods for the administration of certain VMAT2 inhibitors 14 Aug, 2039
Active
US11654142 Methods for the administration of certain VMAT2 inhibitors 14 Nov, 2038
Active
US11026939 High dosage valbenazine formulation and compositions, methods, and kits related thereto 18 Sep, 2038
Active
US11311532 High dosage valbenazine formulation and compositions, methods, and kits related thereto 18 Sep, 2038
Active
US10857137 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
Active
US10857148 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
Active
US10874648 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
Active
US10912771 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
Active
US10952997 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
Active
US10993941 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
Active
US11040029 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
Active
US11439629 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
Active
US10906902 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) 22 Dec, 2036
Active
US10906903 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) 22 Dec, 2036
Active
US10919892 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) 22 Dec, 2036
Active
US10065952 Valbenazine salts and polymorphs thereof 28 Oct, 2036
Active
US10844058 Valbenazine salts and polymorphs thereof 28 Oct, 2036
Active
US10851103 Valbenazine salts and polymorphs thereof 28 Oct, 2036
Active
US10851104 Valbenazine salts and polymorphs thereof 28 Oct, 2036
Active
US10905690 Treatment of congenital adrenal hyperplasia 21 Jan, 2035
Active
US11311544 Treatment of congenital adrenal hyperplasia 21 Jan, 2035
Active
US11730739 Treatment of congenital adrenal hyperplasia 21 Jan, 2035
Active
US8039627 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto 11 Apr, 2031
Active
US8357697 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto 08 Nov, 2027
Active


Given below is the list of recent legal activities going on the following drug patents of Neurocrine.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 04 Mar, 2026 US10065952
Payment of Maintenance Fee, 8th Year, Large Entity 04 Mar, 2026 US10065952
transaction for FDA Determination of Regulatory Review Period 13 Feb, 2026 US11311544
transaction for FDA Determination of Regulatory Review Period 13 Feb, 2026 US10905690
transaction for FDA Determination of Regulatory Review Period 13 Feb, 2026 US11730739
transaction for FDA Determination of Regulatory Review Period 02 Dec, 2025 US10905690
transaction for FDA Determination of Regulatory Review Period 02 Dec, 2025 US11730739
transaction for FDA Determination of Regulatory Review Period 02 Dec, 2025 US11311544
Second letter to regulating agency to determine regulatory review period 27 Oct, 2025 US11311544
Second letter to regulating agency to determine regulatory review period 27 Oct, 2025 US10905690
Payment of Maintenance Fee, 4th Year, Large Entity 27 Oct, 2025 US11311532
Payment of Maintenance Fee, 4th Year, Large Entity 27 Oct, 2025 US11311544
Payment of Maintenance Fee, 4th Year, Large Entity 27 Oct, 2025 US11311532
Second letter to regulating agency to determine regulatory review period 27 Oct, 2025 US11730739
Information Disclosure Statement (IDS) Filed 08 Oct, 2025 US11311544


Neurocrine's Family Patents

Neurocrine drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 27.8% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents





Clinical Trials

Recent Clinical Trials by Neurocrine:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism Neurocrine UK Limited NA COMPLETED
(Sep 1, 2026)
PHASE1
An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone Neurocrine UK Limited NA COMPLETED
(Sep 1, 2026)
PHASE1
A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations Neurocrine UK Limited NA COMPLETED
(Sep 1, 2026)
PHASE1
Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration Neurocrine UK Limited NA COMPLETED
(Sep 1, 2026)
PHASE1
A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects Neurocrine UK Limited NA COMPLETED
(Sep 1, 2026)
PHASE1
A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects Neurocrine UK Limited NA COMPLETED
(Sep 1, 2026)
PHASE1
Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy Neurocrine UK Limited NA WITHDRAWN
(Sep 1, 2026)
PHASE3
Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency Neurocrine UK Limited NA COMPLETED
(Sep 1, 2026)
PHASE2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old Neurocrine Switzerland GmbH NA RECRUITING
(Sep 1, 2026)
PHASE2
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old Neurocrine Switzerland GmbH NA ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia Neurocrine Biosciences NA ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE3


Neurocrine Drug List

Given below is the complete list of Neurocrine's drugs and the patents protecting them.


1. Crenessity

Crenessity is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12582634 Synthetic Methods For Preparation Of 4-(2-Chloro-4-Methoxy-5-Methylphenyl)-N-[(1S)-2-Cyclopropyl-1-(3-Fluoro-4-Methylphenyl)Ethyl]-5-Methyl-N-Prop-2-Ynyl-1,3-Thiazol-2-Amine 12 Jan, 2043
(16 years from now)
Active
US12128033 Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine 09 Jun, 2041
(14 years from now)
Active
US10905690 Treatment of congenital adrenal hyperplasia 21 Jan, 2035
(8 years from now)
Active
US11311544 Treatment of congenital adrenal hyperplasia 21 Jan, 2035
(8 years from now)
Active
US11730739 Treatment of congenital adrenal hyperplasia 21 Jan, 2035
(8 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Crenessity's drug page


2. Ingrezza

Ingrezza is protected by 22 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10940141 Methods for the administration of certain VMAT2 inhibitors 10 Aug, 2040
(13 years from now)
Active
US11026931 Methods for the administration of certain VMAT2 inhibitors 14 Aug, 2039
(12 years from now)
Active
US11654142 Methods for the administration of certain VMAT2 inhibitors 14 Nov, 2038
(12 years from now)
Active
US11026939 High dosage valbenazine formulation and compositions, methods, and kits related thereto 18 Sep, 2038
(11 years from now)
Active
US11311532 High dosage valbenazine formulation and compositions, methods, and kits related thereto 18 Sep, 2038
(11 years from now)
Active
US10857137 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US10857148 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US10874648 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US10912771 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US10952997 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US10993941 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US11040029 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US11439629 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US10906902 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) 22 Dec, 2036
(10 years from now)
Active
US10906903 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) 22 Dec, 2036
(10 years from now)
Active
US10919892 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) 22 Dec, 2036
(10 years from now)
Active
US10065952 Valbenazine salts and polymorphs thereof 28 Oct, 2036
(10 years from now)
Active
US10844058 Valbenazine salts and polymorphs thereof 28 Oct, 2036
(10 years from now)
Active
US10851103 Valbenazine salts and polymorphs thereof 28 Oct, 2036
(10 years from now)
Active
US10851104 Valbenazine salts and polymorphs thereof 28 Oct, 2036
(10 years from now)
Active
US8039627 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto 11 Apr, 2031
(4 years from now)
Active
US8357697 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto 08 Nov, 2027
(1 year, 28 days from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ingrezza's drug page


3. Ingrezza Sprinkle

Ingrezza Sprinkle is protected by 22 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10940141 Methods for the administration of certain VMAT2 inhibitors 10 Aug, 2040
(13 years from now)
Active
US11026931 Methods for the administration of certain VMAT2 inhibitors 14 Aug, 2039
(12 years from now)
Active
US11654142 Methods for the administration of certain VMAT2 inhibitors 14 Nov, 2038
(12 years from now)
Active
US11026939 High dosage valbenazine formulation and compositions, methods, and kits related thereto 18 Sep, 2038
(11 years from now)
Active
US11311532 High dosage valbenazine formulation and compositions, methods, and kits related thereto 18 Sep, 2038
(11 years from now)
Active
US10857137 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US10857148 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US10874648 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US10912771 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US10952997 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US10993941 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US11040029 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US11439629 Methods for the administration of certain VMAT2 inhibitors 10 Oct, 2037
(11 years from now)
Active
US10906902 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) 22 Dec, 2036
(10 years from now)
Active
US10906903 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) 22 Dec, 2036
(10 years from now)
Active
US10919892 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) 22 Dec, 2036
(10 years from now)
Active
US10065952 Valbenazine salts and polymorphs thereof 28 Oct, 2036
(10 years from now)
Active
US10844058 Valbenazine salts and polymorphs thereof 28 Oct, 2036
(10 years from now)
Active
US10851103 Valbenazine salts and polymorphs thereof 28 Oct, 2036
(10 years from now)
Active
US10851104 Valbenazine salts and polymorphs thereof 28 Oct, 2036
(10 years from now)
Active
US8039627 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto 11 Apr, 2031
(4 years from now)
Active
US8357697 Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto 08 Nov, 2027
(1 year, 28 days from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ingrezza Sprinkle's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Neurocrine News

Neurocrine Acquires Soleno for $2.9 Billion, Potentially Securing Its Next Major Pharmaceutical Success

06 Apr, 2026

See More